CASI Pharmaceuticals Inc. (CASI) is a clinical stage company with cancer treatment drugs in phase I and phase II. CASI has a market cap of $59 million with a stock price at $1.84 a share. Shares have reached a 52-week high of $2.13 on June 17, 2015 and a low of $1.07 in December 2014.
Currently company insiders own 37% of CASI Pharmaceuticals company shares with institutional investors holding 14%. CASI stock has a 50-Day MA of $1.52 and a 200-Day MA of $1.51. CASI reported $9.46 million in total cash and $1.41 in debt as of March 31, 2015 with a cash burn rate of about $4 million annually.
Curis, Inc. (CRIS) has 6 cancer treatment products in its product pipeline, one which is currently being marketed. Curis, Inc. stock is currently trading at $3.12 per share with a market cap of about $400 million. The stock has done well in the last 12 months gaining over 200% from $1.10 a share to a high of $3.65 a share on June 2, 2015. Many Wall Street analysts are bullish on CRIS with projections of $5 to $7 per share. The next earnings report is scheduled in early August.
Another small cap stock to watch in the pharmaceutical biotech arena is Exelixis, Inc. (EXEL). EXEL develops cancer treatment drugs and are involved in two Phase III trials. Exelixis, Inc. has a market cap of $723 million with a current stock price of $3.58 per share. EXEL stock has a 52-week high of $4.55 a share on July 28, 2014 and a low of $1.26 per share in late December 2014.
